# Overview of 4 potential routes for increase researcher access



#### Outline

- Overarching goals
- Open Access
- Streamlined access
- Researcher commons
- Central server





#### Goals

- Improve researcher access to datasets consistent with consents
  - Improves targeted research
  - Required for serendipitous studies
- Compliance with consents is not a zero-sum game with researcher access
- Research participants overwhelming want to see this happen
  - This fact is rediscovered multiple times



## 80/20 solution

- We should not let the 1% or 10% or even 20% of "edge cases" prevent a good solution for 80% or more of the data. Instead find a pragmatic, acceptable solution for the majority of the data, and special case the ones which don't fit.
- Historical consents always a bad idea to be held hostage to historical scenarios. Reconsenting is annoying by often feasible.
- Special cases Drug addiction, sexual behaviour etc. should not dominate the debate – place into a special case scenario, and expect to handle these differently



# **Open Access**





# **Open Access proposal**

- Have anonymised identifiers for genotype and phenotype information
- Ensure the consent process informs the participant of risks
- Totally maximises the serendipity for reuse.
- Is already in widespread use for molecular-only studies (HapMap etc)
- ? Could be extended for other normal phenotypes?
- ? Is being extended for disease phenotypes (PGP)





- Pros
- 0 headache in researcher access
- Maximal reuse of data
- Most likely to generate serendipitous discoveries

- Cons
- Small but higher than other schemes risk of participant harm
- Unknown risk of lack of participation, in particular by disadvantaged groups
- Harder sell to local IRB boards and current practice

# **Streamlined Access**





# Streamline current system

- Sensible proposal for improving the current system
- 8 major points: consolidate DACs, share more language + terms, have broad consents
- Proposal to change policy (Homer etal): Release genotype numbers.





- Pros
- Improves researcher access
- Sets up future broad consents
- Releasing genotype numbers (and therefore Pvalues) provides for broad reuse

- Cons
- Potential, v. low risk of participation in a study via genotype number and genotypes
- Perpetuates current system, providing less impetus for deeper reform

# **Researcher Commons**





# **Researcher Commons**

- In effect, pre-authorisation of researchers for broad consents
- Can be consistent with current broad consents (so no change in relationship between researcher and participant)
- Practical benefits for broad research use
- Needs a certification authority
- Can be internationalised





- Pros
- Improves researcher access
- Serendipitous research more easily achieved
- Provides context for centralised (institutional or broader) systems

- Cons
- Reputational risk of researchers changing the rules to suite them
- Perpetuates current system, providing less impetus for deeper reform

# Central server that provides analysis results

- Different levels:
  - Imputation
  - Stats models
  - Pvalue server
  - Curated variants
- Particular suggestion
  - Low level data kept private
  - People can use a cloud like infrastructure for flexibility



- Pros
- Enables more research over datasets
- Might provide a midlevel access option (cloud not raw access)
- Heavy lifting happens once

- Cons
- Centralising might cause I/O or people (helpdesk) bottleneck
- (Focused on high to mid level analysts – Pvalue lists just as useable)

# Ewan Birney's overview





#### These are not mutually incompatible

- Streamlining research is good
  - And sets up the way for Researcher Commons
  - Genotypes/Pvalues good
- Researcher commons is good
  - And will change the view of broad sets of data
- Open access is great, and already being used
  - And should continue molecular/ normal phenotypes?
- Central servers are worth trying
  - Not the only solution



# Something old, something new

- Established resources
  - dbGap, EGA
  - UCSC, Ensembl, Entrez
- Emerging resources
  - BioSamples (EBI/NCBI)
  - PRIDE, ICGC Portal, CGHub, Galaxy …
- New resources
  - <your whizzy idea here>



#### These are not mutually incompatible

- Streamlining research is good
  - And sets up the way for Researcher Commons
  - Genotypes/Pvalues good
- Researcher commons is good
  - And will change the view of broad sets of data
- Open access is great, and already being used
  - And should continue molecular/ normal phenotypes?
- Central servers are worth trying
  - Not the only solution

